Cryoshippers for Cell and Gene Therapy Market Report Scope & Overview:

Cryoshippers for Cell and Gene Therapy Market was valued at USD 1.65 billion in 2025 and is expected to reach USD 5.20 billion by 2035, growing at a CAGR of 12.23% from 2026-2035. 

The Cryoshippers for Cell and Gene Therapy Market is witnessing strong growth as a result of the rapid emergence of the development and commercialization of cell and gene therapies that need a secure and reliable temperature-controlled transport process. The main reason for this is that cryoshippers can ensure ultra-cold temperatures to help preserve the viability, potency, and quality of biological materials during transport. Factors like increased clinical trials, manufacturing of cell and gene therapies, and transfer of biological samples between laboratories, manufacturing sites, and therapeutic locations have led to increased demand in the market.

The FDA's continuously expanding list of approved cellular and gene therapy products demonstrates the increasing commercialization of advanced therapies and the resulting need for reliable distribution infrastructure.

Market Size and Forecast

• Market Size in 2026E: USD 1.84 Billion

• Market Size by 2035: USD 5.20 Billion

• CAGR: 12.23% from 2026 to 2035

• Fastest Growing Region: Asia Pacific

• Largest Region: North America

Cryoshippers for Cell and Gene Therapy Market Trends

• Rising adoption of cell and gene therapies is driving demand for reliable cryoshipping solutions that maintain ultra-low temperatures during transportation.

• Increasing clinical trials and commercialization of advanced therapies are expanding requirements for temperature-controlled logistics and specialized cryogenic shipping systems.

• Growing global distribution of cell and gene therapy products is encouraging adoption of validated cryoshippers for safe long-distance transportation.

• Advancements in dry vapor technology and insulation materials are improving temperature stability, holding times, durability, and shipping performance.

• Increasing regulatory requirements for maintaining product integrity throughout the cold chain are strengthening demand for validated and compliant cryoshipping solutions.

U.S. Cryoshippers for Cell and Gene Therapy Market Outlook

U.S. Cryoshippers for Cell and Gene Therapy Market was valued at USD 0.59 billion in 2025 and is expected to reach USD 1.86 billion by 2035, growing at a CAGR of 12.23% from 2026-2035. 

The U.S. Cryoshippers for Cell and Gene Therapy Market is experiencing tremendous growth owing to the growth in the development and commercialization of cell and gene therapies and the requirement for efficient temperature-controlled shipping. Cryoshippers keep biological material viable and potent by ensuring that they are transported in ultra-low temperatures. The growth is being fueled by increased clinical studies, the manufacturing of more cell and gene therapies, and the increased movement of such products between laboratories, manufacturers, and treatment centers. Furthermore, cryogenics, tracking, and packaging innovations have improved the efficiency of the transportation process.

The Alliance for Regenerative Medicine reported more than 3,000 clinical-stage advanced therapy programs globally, highlighting the expanding pipeline of cell and gene therapies requiring specialized logistics.

Cryoshippers for Cell and Gene Therapy Market Segment Analysis  

• By Product Type, Dry Shippers dominated the Cryoshippers for Cell and Gene Therapy Market with 44% share in 2025; Liquid Nitrogen Shippers are expected to grow at the fastest CAGR of 13.37% from 2026–2035.

• By Application, Cell Therapy dominated the Cryoshippers for Cell and Gene Therapy Market with 29% share in 2025; Gene Therapy is expected to grow at the fastest CAGR of 13.62% from 2026–2035.

• By End User, Biopharmaceutical Companies dominated the Cryoshippers for Cell and Gene Therapy Market with 39% share in 2025; Hospitals & Clinics are expected to grow at the fastest CAGR of 14.51% from 2026–2035.

• By Capacity, 10–20 Liters dominated the Cryoshippers for Cell and Gene Therapy Market with 39% share in 2025; Above 20 Liters is expected to grow at the fastest CAGR of 12.99% from 2026–2035.

By Product Type, Dry Shippers dominate the cryoshippers for cell and gene therapy market, Liquid Nitrogen Shippers grow fastest.

Dry Shippers segment dominated the Cryoshippers for Cell and Gene Therapy Market with the highest revenue share of about 44% in 2025 Due to their capability of maintaining cryogenic temperatures without the use of liquid nitrogen during transit. They are safer, regulatory compliant, spill-proof, and effective in temperature retention making them ideal for biological specimens. The increased shipment of cell and gene therapy samples makes them even more popular.

Liquid Nitrogen Shippers segment is expected to grow at the fastest CAGR of 13.37% from 2026-2035 This is due to the rising requirement for long-term cryogenic storage and transportation of biological materials that require preservation at low temperatures. These devices ensure effective temperature management for long periods of time. Rising numbers of clinical trials and distribution across the globe are set to boost their demand.

By Application, Cell Therapy dominates the cryoshippers for cell and gene therapy market, Gene Therapy grows fastest.

Cell Therapy segment dominated the Cryoshippers for Cell and Gene Therapy Market with the highest revenue share of about 29% in 2025 this is because of increased development and commercialization of cellular therapies that require precise control over cryogenic temperatures. Cryoshippers ensure cellular viability during transport between production plants, clinics, and other locations where the cells will be used for treatment.

Gene Therapy segment is expected to grow at the fastest CAGR of 13.62% from 2026-2035 due to rising development of sophisticated gene therapies. Gene therapies need temperature control for their stability during transport. Rising regulatory approvals, investment in gene therapies production, and increased use in clinical settings are expected to drive growth in the global cryogenic shipping market.

By End User, Biopharmaceutical Companies dominate the cryoshippers for cell and gene therapy market, Hospitals & Clinics grow fastest.

Biopharmaceutical Companies segment dominated the Cryoshippers for Cell and Gene Therapy Market with the highest revenue share of about 39% in 2025 As a result of the high level of participation in the development, production, storage, and distribution of cell and gene therapies. The firms need dependable cryogenic transport for quality control in the process. Pipeline growth and clinical trials also support the demand for cryoshippers worldwide.

Hospitals & Clinics segment is expected to grow at the fastest CAGR of 14.51% from 2026-2035 This is attributed to increased administration of cell and gene therapy and increase in the number of specialized treatment centers. There is need for a reliable cryoshipper that will transport such therapies, which have sensitive temperature requirements, from the manufacturing firm and specialized centers. Increased clinical adoption and availability will drive the global market.

By Capacity, 10–20 Liters dominates the cryoshippers for cell and gene therapy market, Above 20 Liters grows fastest.

10–20 Liters segment dominated the Cryoshippers for Cell and Gene Therapy Market with the highest revenue share of about 39% in 2025 because of its balanced design regarding its storage capacity, portability, heat preservation, and ease of transportation. This capacity will work well for a variety of clinical and business transports that need controlled cryogenic storage conditions. The need for distribution of therapies and shipping solutions is increasing.

Above 20 Liters segment is expected to grow at the fastest CAGR of 12.99% from 2026-2035 due to the rising amounts of cellular and genetic therapy products that need to be shipped from manufacturing sites to distribution centers and treatment centers. The larger cryoshippers mean higher load capacity and less frequent shipments. It is anticipated that the rising commercialization and globalization of therapies will increase adoption.

Regional Analysis

North America Cryoshippers for Cell and Gene Therapy Market Insights 

North America dominated the Cryoshippers for Cell and Gene Therapy Market with the highest market share of about 39% in 2025, due to state-of-the-art facilities for cell and gene therapy, increased clinical trials, and flourishing pharmaceutical and biotech industry. Growing need for temperature-controlled logistics, presence of cold chain systems, and investment in regenerative medicine are also adding momentum to cryogenic shipping solutions.

The U.S. Cryoshippers for Cell and Gene Therapy Market accounted for a market share of 91.0%, backed by state-of-the-art facilities for cell and gene therapy, robust clinical research activities, and strong pharmaceutical and biotech sectors. Factors such as growing need for temperature-controlled shipments, presence of a cold chain network, and increased commercialization of advanced therapies are fueling market growth.

Europe Cryoshippers for Cell and Gene Therapy Market Insights

Europe Cryoshippers for Cell and Gene Therapy Market is experiencing consistent growth, driven by growing cell and gene therapy research, rising clinical trials, and sophisticated pharmaceutical infrastructure. Increasing demand for temperature-controlled transportation is helping in the rise of cryogenic transportation. Investments in advanced therapies manufacturing, cold-chain logistics, biobanking, personalized medicines, and favorable regulations are additional factors driving the growth of the region’s market.

The Germany Cryoshippers for Cell and Gene Therapy Market accounted for a market share of 23.5%, fueled by growing research into cell and gene therapies, clinical trials, and pharmaceuticals infrastructure. The growing need for reliable cryogenic transport systems is fueling the development of the market. Biobanking, advanced therapy manufacturing, cold chain logistics, and personalized medicine investments, together with research and regulations, are driving adoption further.

Asia Pacific Cryoshippers for Cell and Gene Therapy Market Insights

Asia Pacific is expected to grow at the fastest CAGR of about 13.34% from 2026–2035, backed by advances in cell therapy studies, gene therapy studies, and greater clinical trials, and increased funding in biotechnology. The growth of the healthcare infrastructure, pharmaceutical production, and the need for effective cryogenic logistics is propelling the process.

The China Cryoshippers for Cell and Gene Therapy Market accounted for a market share of 41.0%, backed by improvements in biotechnological expertise, cell and gene therapies’ clinical studies, and pharmaceutical companies’ investment. The growing need for temperature-controlled transportation systems is the reason behind this trend. Improvement in advanced therapy production, cold chain logistics, biobankings, and biotechnological innovations encouraged by the government is enhancing China’s competitiveness in the market.

Middle East & Africa and Latin America Cryoshippers for Cell and Gene Therapy Market Insights

The Middle East & Africa and Latin America Cryoshippers for Cell and Gene Therapy Market is expanding progressively due to increasing investments in biotechnology, clinical research, and healthcare infrastructure. The rising popularity of cell and gene therapies is driving the need for cryogenic shipping. The establishment of cold-chain logistics, pharma partnerships, advanced therapies manufacturing, and healthcare upgrades is fueling growth in the regional market.

The UAE Cryoshippers for Cell and Gene Therapy Market accounted for a market share of 18.0%, This is supported by increased spending in healthcare, growth in biotech innovations, and the rising demand for advanced treatments. Opportunities are being created through the growth of specialized healthcare facilities and demand for secure cryogenic transport. Other contributing factors include government-driven innovation in healthcare, pharmaceutical partnerships across nations, cold chain development, and cell/gene therapy R&D.

Market Dynamics

Growth Drivers: Growing cell and gene therapy pipelines are accelerating demand for reliable cryogenic transportation solutions across healthcare networks globally

The rapid expansion of cell and gene therapy development is significantly driving demand for specialized cryoshippers. Many times, the shipment of such drugs necessitates the use of temperature-controlled transport methods in order to maintain their cell viability, quality and efficacy. The increasing number of clinical studies and commercialization of these therapies is leading to an increased need for cryogenic logistics services in order to maintain the link between manufacturing facilities, hospitals, research centers and patients. Cryoshippers offer controlled low temperatures that can contribute to the protection of these temperature-sensitive drugs during their shipment process. The increased usage of autologous and allogeneic therapy is causing even more shipments and logistics needs.

Restraints: High equipment costs and complex handling requirements can limit adoption of advanced cryoshippers among smaller therapy providers

High acquisition and operating costs remain significant challenges for the Cryoshippers for Cell and Gene Therapy Market. Cryogenically advanced shipping systems use particular types of insulation, vacuum technology, cooling techniques, sturdy construction, and validation of the shipping system to ensure that the low temperatures are maintained throughout the shipping process. The reusable cryoshippers can also be subject to cleaning, inspection, maintenance, and safe return shipping logistics, adding further to the cost of owning such a shipping system. This may prove to be a hard task for small biotech firms, research centers, and clinical facilities, especially during the developmental stage of therapy when the volume of shipments is still low. There may also be the need for specialist staff to prepare, pack, load, and un-pack the cryogenic containers.

Opportunities: Rapid expansion of commercial cell and gene therapies creates significant opportunities for advanced cryoshipper manufacturers globally

The increasing commercialization of cell and gene therapies is creating substantial opportunities for cryoshipper manufacturers. The emergence of more sophisticated treatments moving from clinical trials to commercial production increases the need for a robust transportation system to connect manufacturers, treatment centers, laboratories, and patients. For supply chains to work at the commercial level, cryoshippers have to be designed with extended hold times, temperature control, product protection, and regulatory compliance. With the increasing use of autologous and allogeneic treatments, there is an increased need for cryoshippers that allow for flexibility in dealing with different product quantities and logistics. Differentiation in this area can be done by introducing reusable cryoshippers, improved insulation, light-weightedness, and robustness.

Recent Developments:

• 2026 : Cryoport Systems continued expanding its cryogenic shipping portfolio with LN₂ dry-vapor systems maintaining temperatures at or below -150°C, supporting cell therapies, gene therapies, and other sensitive biologics with monitoring and traceability.

• 2026 : Peli BioThermal continued advancing its temperature-controlled packaging solutions for advanced therapies, supporting the secure transportation of cell and gene therapy products through validated thermal protection and specialized logistics technologies.

• 2026 : Thermo Fisher Scientific continued strengthening its cryogenic supply-chain capabilities for advanced therapies, supporting temperature-sensitive biological materials through specialized packaging, cold-chain, and logistics solutions.

• 2025 : BioLife Solutions continued expanding its cell and gene therapy preservation ecosystem, integrating cryogenic storage and transportation technologies designed to maintain product integrity throughout advanced-therapy supply chains.

Cryoshippers for Cell and Gene Therapy Market key players are:

• Thermo Fisher Scientific Inc.

• Cryoport, Inc.

• Chart Industries, Inc.

• Sartorius AG

• BioLife Solutions, Inc.

• Azenta Life Sciences, Inc.

• Avantor, Inc.

• PHC Holdings Corporation

• Worthington Industries, Inc.

• Haier Biomedical

• Taylor-Wharton

• IC Biomedical

• Cryogenic Control Systems, Inc.

• Cryofab, Inc.

• Custom Biogenic Systems

• CryoSafe

• CryoLogic Pty Ltd

• Statebourne Cryogenics

• Linde plc

• Peli BioThermal

Cryoshippers for Cell and Gene Therapy Market Report Scope: